[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 126
1. Golovastova MO, Tsoy LV, Bocharnikova AV, Korolev DO, Gancharova OS, Alekseeva EA, Kuznetsova EB, Savvateeva LV, Skorikova EE, Strelnikov VV, Varshavsky VA, Vinarov AZ, Nikolenko VN, Glybochko PV, Zernii EY, Zamyatnin AA Jr, Bazhin AV, Philippov PP: The cancer-retina antigen recoverin as a potential biomarker for renal tumors. Tumour Biol; 2016 Jul;37(7):9899-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal cell carcinoma is the ninth most common cancer with an increasing occurrence and mortality.
  • In this work, we demonstrated that recoverin is indeed expressed in 68.4 % of patients with different subtypes of renal cell carcinoma, and this expression has tendency to correlate with tumor size.
  • Interestingly, 91.7 % of patients with the benign renal tumor, oncocytoma, express recoverin as well in their tumor.
  • This work is the first report pointing towards the association of overall survival of renal cell carcinoma (RCC) patients with promoter methylation of a cancer-retina antigen.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. DNA Methylation. Kidney Neoplasms / pathology. Recoverin / metabolism

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Dermatol. 2010 Nov;19(11):1023-5 [20812967.001]
  • [Cites] Clin Cancer Res. 2013 Dec 1;19(23 ):6544-6555 [24088737.001]
  • [Cites] Curr Mol Med. 2015;15(5):462-8 [26122656.001]
  • [Cites] Biochem Biophys Res Commun. 2013 Jun 14;435(4):526-32 [23643812.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jan;56(1):110-6 [16444517.001]
  • [Cites] Cancer Lett. 2014 May 1;346(2):178-87 [24462820.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):117-25 [16432832.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):448-53 [12216073.001]
  • [Cites] J Cell Biol. 1991 Mar;112(5):981-9 [1999465.001]
  • [Cites] PLoS One. 2014 Sep 03;9(9):e106290 [25184628.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8 [12613443.001]
  • [Cites] Am J Surg Pathol. 2013 Oct;37(10):1469-89 [24025519.001]
  • [Cites] BMC Cancer. 2014 Jan 31;14:54 [24485021.001]
  • [Cites] J Carcinog. 2007 May 04;6:9 [17477881.001]
  • [Cites] Int Rev Immunol. 2012 Oct;31(5):321-43 [23083344.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1268-76 [17187367.001]
  • [Cites] J Cell Mol Med. 2013 Aug;17(8):1048-58 [23890189.001]
  • [Cites] Int J Oncol. 2012 May;40(5):1650-8 [22327210.001]
  • [Cites] Biochemistry (Mosc). 2014 Aug;79(8):733-9 [25365483.001]
  • [Cites] Epigenetics. 2014 Apr;9(4):579-86 [24452105.001]
  • [Cites] Nat Rev Urol. 2012 Jun 19;9(7):386-96 [22710665.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):590-5 [11431713.001]
  • [Cites] Int J Mol Med. 1998 Jul;2(1):57-60 [9854143.001]
  • [Cites] Lung Cancer. 2004 May;44(2):193-8 [15084384.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):140-9 [18814277.001]
  • [Cites] J Urol. 2013 Jul;190(1):291-301 [23391467.001]
  • [Cites] FEBS Lett. 1995 Nov 27;376(1-2):87-90 [8521974.001]
  • [Cites] Crit Rev Immunol. 2012;32(2):97-126 [23216610.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):537-44 [9195569.001]
  • [Cites] BMJ. 2014 Nov 10;349:g4797 [25385470.001]
  • [Cites] Oncol Lett. 2014 Apr;7(4):1021-1026 [24944662.001]
  • [Cites] Biochemistry (Mosc). 2011 Mar;76(3):332-8 [21568868.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):247-57 [15848735.001]
  • [Cites] Curr Med Chem. 2007;14(23):2489-94 [17979702.001]
  • [Cites] Urology. 2014 Jan;83(1):256.e9-14 [24239027.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1126-30 [12429790.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):583-9 [15800613.001]
  • [Cites] Oncol Lett. 2012 Feb;3(2):377-382 [22740915.001]
  • [Cites] CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 [22237781.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Biomed Res Int. 2015;2015:367354 [26161397.001]
  • [Cites] Int J Cancer. 2014 Jun 1;134(11):2615-25 [24395279.001]
  • [Cites] BMC Cancer. 2011 Mar 31;11:115 [21453469.001]
  • [Cites] Science. 1993 Feb 5;259(5096):829-32 [8430337.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8240-8 [18922895.001]
  • [Cites] Ophthalmic Res. 2010;43(3):139-44 [19887879.001]
  • (PMID = 26813565.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 135844-11-0 / Recoverin
  • [Keywords] NOTNLM ; Cancer-retina antigens / DNA methylation / Onconeural antigens / Recoverin / Renal cancer
  •  go-up   go-down


2. Pereira BD, Rios ES, Cabrera RA, Portugal J, Raimundo L: Adrenocortical oncocytoma presenting as Cushing's syndrome: an additional report of a paediatric case. Endocr Pathol; 2014 Dec;25(4):397-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical oncocytoma presenting as Cushing's syndrome: an additional report of a paediatric case.
  • We present a preschool child developing Cushing's syndrome due to an adrenocortical oncocytoma, which was confirmed immunohistochemically with antibodies to the mitochondrial electron complex 2.
  • Using the Lin-Weiss-Bisceglia score system and the reticulin algorithm, this tumour was categorized as a benign adrenocortical oncocytoma.
  • To our knowledge, we herein present the youngest patient developing an adrenocortical oncocytoma and the first manifestation of Cushing's syndrome due to this rare neoplasm in paediatric patients.
  • We also emphasize the clinical usefulness of immunohistochemistry to the mitochondrial enzyme succinate dehydrogenase to confirm the oxyphilic nature of adrenocortical oncocytomas.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adrenal Cortex Neoplasms / diagnosis. Cushing Syndrome / diagnosis

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):867-81 [12826878.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):871-7 [15572420.001]
  • [Cites] Pediatr Dev Pathol. 2009 Jul-Aug;12(4):284-91 [19326954.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] J Pediatr Surg. 2008 May;43(5):E1-3 [18485928.001]
  • [Cites] Acta Otorrinolaringol Esp. 2011 Sep-Oct;62(5):355-62 [21561594.001]
  • [Cites] J Korean Med Sci. 2010 Jul;25(7):1077-9 [20592902.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Virchows Arch. 2009 May;454(5):481-95 [19343360.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):718-21 [17091483.001]
  • [Cites] Hum Pathol. 2011 Apr;42(4):489-99 [21237489.001]
  • [Cites] Am J Surg Pathol. 2011 Dec;35(12):1882-93 [21989346.001]
  • [Cites] Hinyokika Kiyo. 1986 May;32(5):757-63 [3751804.001]
  • [Cites] AJR Am J Roentgenol. 2011 Mar;196(3):592-6 [21343501.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] J Clin Pathol. 1986 Aug;39(8):908-12 [2427550.001]
  • [Cites] JBR-BTR. 2004 Jul-Aug;87(4):180-2 [15487257.001]
  • [Cites] Fam Cancer. 2012 Jun;11(2):189-94 [22160509.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Sep;95(9):4106-13 [20823463.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Am J Clin Pathol. 2012 Apr;137(4):612-8 [22431538.001]
  • [Cites] Am J Surg Pathol. 2013 Sep;37(9):1433-40 [23774167.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 25077961.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.3.5.1 / Electron Transport Complex II; EC 1.3.5.1 / SDHA protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; Acth-Independent Macronodular Adrenal Hyperplasia
  •  go-up   go-down


3. Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM: MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Med; 2016 Apr;5(4):656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
  • Clear cell renal cell carcinoma (ccRCC) is the most prevalent adult kidney cancer.
  • In a cohort of 234 patients with primary ccRCC, we correlated miR-194 expression level with multiple clinicopathological features including disease-free and overall survival, tumor size, clinical stage, and histological grade.
  • Additionally, patients with higher miR-194 expression has significantly longer disease-free survival (P = 0.041) and overall survival (P = 0.031) compared to those with lower expression.
  • In multivariate analysis, miR-194-positive tumors retain significance in disease-free survival and overall survival, suggesting miR-194 is an independent marker for good prognosis in ccRCC.
  • We also compared miR-194 expression between RCC subtypes. ccRCC had the highest levels, whereas chromophobe RCC and oncocytoma had comparable lower levels.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / mortality. Kidney Neoplasms / genetics. Kidney Neoplasms / mortality. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Computational Biology / methods. Databases, Genetic. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Grading. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
  • [Cites] Eur J Cancer Prev. 2002 Apr;11(2):171-8 [11984136.001]
  • [Cites] Cytoskeleton (Hoboken). 2015 Nov;72(11):557-69 [26543012.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] J Urol. 2006 Apr;175(4):1235-9 [16515968.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2353-8 [17085101.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):193-205 [18313224.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10094-104 [19074875.001]
  • [Cites] Annu Rev Med. 2009;60:167-79 [19630570.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5794-9 [19826129.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):369-78 [20012925.001]
  • [Cites] Cancer Cell. 2010 Oct 19;18(4):367-81 [20951946.001]
  • [Cites] Hepatology. 2010 Dec;52(6):2148-57 [20979124.001]
  • [Cites] Eur Urol. 2011 May;59(5):721-30 [21272993.001]
  • [Cites] J Urol. 2011 Sep;186(3):1077-83 [21784468.001]
  • [Cites] Eur Urol. 2011 Oct;60(4):615-21 [21741761.001]
  • [Cites] Mol Cancer. 2011;10:99 [21851624.001]
  • [Cites] Br J Cancer. 2011 Nov 22;105(11):1741-9 [22033272.001]
  • [Cites] Tumour Biol. 2012 Feb;33(1):131-40 [22086373.001]
  • [Cites] Carcinogenesis. 2012 May;33(5):1014-21 [22431721.001]
  • [Cites] PLoS One. 2012;7(5):e35661 [22623952.001]
  • [Cites] Int J Biol Sci. 2012;8(10):1363-74 [23139634.001]
  • [Cites] Clin Chem. 2013 Jan;59(1):158-67 [23284016.001]
  • [Cites] Nature. 2013 Jul 4;499(7456):43-9 [23792563.001]
  • [Cites] Carcinogenesis. 2013 Oct;34(10):2231-9 [23715501.001]
  • [Cites] Cancer Lett. 2014 Jan 28;342(2):264-74 [22198482.001]
  • [Cites] BJU Int. 2014 Feb;113(2):228-35 [23890347.001]
  • [Cites] Dig Dis Sci. 2014 Sep;59(9):2145-52 [24748184.001]
  • [Cites] Korean J Urol. 2014 Sep;55(9):568-73 [25237457.001]
  • [Cites] BMJ. 2014;349:g4797 [25385470.001]
  • [Cites] J Cancer Res Ther. 2014 Oct-Dec;10(4):1076-81 [25579557.001]
  • [Cites] J Mol Diagn. 2015 Mar;17(2):136-44 [25555365.001]
  • [Cites] Am J Pathol. 2015 Mar;185(3):693-703 [25572155.001]
  • [Cites] Sci Rep. 2015;5:8997 [25757764.001]
  • [Cites] Hum Pathol. 2015 May;46(5):673-80 [25704627.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • (PMID = 26860079.001).
  • [ISSN] 2045-7634
  • [Journal-full-title] Cancer medicine
  • [ISO-abbreviation] Cancer Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN194 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC4831284
  • [Keywords] NOTNLM ; Kidney cancer / metastasis / miR-194 / miRNA / personalized medicine / prognosis / prognostic marker / renal cell carcinoma / survival / tumor markers
  •  go-up   go-down


Advertisement
4. Boris RS, Benhammou J, Merino M, Pinto PA, Linehan WM, Bratslavsky G: The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma. J Urol; 2011 Jun;185(6):2050-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.
  • PURPOSE: Managing oncocytoma in the setting of bilateral renal masses is a challenging scenario.
  • Nevertheless, to our knowledge the pathological concordance of an oncocytic neoplasm in 1 kidney with tumors in the contralateral kidney is not known.
  • MATERIALS AND METHODS: We reviewed the records of patients at the National Institutes of Health between 1983 and 2009 who had bilateral renal masses, known pathology bilaterally and oncocytoma or an oncocytic neoplasm in at least 1 kidney.
  • Oncocytoma or an oncocytic neoplasm in 2 renal units was considered concordant.
  • Also, the 8 patients without Birt-Hogg-Dubé syndrome who had multifocal renal masses showed 100% oncocytoma concordance between renal units.
  • Genetic testing for Birt-Hogg-Dubé should be considered in the treatment algorithm of patients with bilateral renal masses and known oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Germ-Line Mutation. Neoplasms, Multiple Primary / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] Urology. 2003 May;61(5):921-5 [12736005.001]
  • [Cites] J Urol. 2003 Apr;169(4):1276-81 [12629342.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):53-7; discussion 57 [14667516.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):615-20 [14713772.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Urol. 1998 Aug;160(2):335-40 [9679872.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1195-202 [10522666.001]
  • [Cites] J Urol. 2005 May;173(5):1482-6 [15821464.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] Urology. 2005 Dec;66(6):1181-5 [16360437.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):321-31 [18234728.001]
  • [Cites] Urology. 2008 Jul;72(1):138-42 [18336882.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Jun;9(6):773-83 [19496714.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3731-3 [19597019.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3737-41 [19597028.001]
  • [Cites] Nat Rev Urol. 2010 May;7(5):277-85 [20448661.001]
  • [Cites] Eur Urol. 2010 Apr;57(4):661-5 [19477583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7 [19850877.001]
  • [Cites] Mayo Clin Proc. 2000 Oct;75(10):1020-6 [11040850.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):330-6 [11684851.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Urol. 2003 Jan;169(1):71-4 [12478106.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • (PMID = 21496834.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC011023-01; United States / NCI NIH HHS / BC / Z01 BC011089-01; United States / NCI NIH HHS / BC / Z01 BC011028-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / BC / Z01 BC011043-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ NIHMS316363; NLM/ PMC3164767
  •  go-up   go-down


5. Spector Y, Fridman E, Rosenwald S, Zilber S, Huang Y, Barshack I, Zion O, Mitchell H, Sanden M, Meiri E: Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol; 2013 Jun;7(3):732-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas.
  • The four most common types of kidney tumors include the malignant renal cell carcinomas; clear cell, papillary, chromophobe and the benign oncocytoma.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / genetics. Kidney / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics. MicroRNAs / genetics. Oligonucleotide Array Sequence Analysis / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • [Cites] Arch Pathol Lab Med. 2012 Apr;136(4):410-7 [22458903.001]
  • [Cites] RNA Biol. 2008 Jul-Sep;5(3):115-9 [19182522.001]
  • [Cites] J Mol Diagn. 2010 Sep;12(5):687-96 [20595629.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):232-44 [19013890.001]
  • [Cites] Arch Pathol Lab Med. 2011 Jan;135(1):92-109 [21204715.001]
  • [Cites] Radiographics. 2009 May-Jun;29(3):741-54; discussion 755-7 [19448113.001]
  • [Cites] Oncologist. 2012;17(6):801-12 [22618571.001]
  • [Cites] J Pathol. 2011 Jan;223(2):102-15 [21125669.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):10-29 [19027455.001]
  • [Cites] BJU Int. 2012 Dec;110(11 Pt C):E1131-7 [22712620.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] FASEB J. 2005 Jun;19(8):875-9 [15923397.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):261-71 [18694565.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] Pathol Res Pract. 2010 Aug 15;206(8):578-84 [20418022.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14 (5):1340-8 [18316553.001]
  • [Cites] J Mol Diagn. 2012 Sep;14(5):510-7 [22749746.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):786-93; discussion 793-4 [16697521.001]
  • [Cites] Urol J. 2011 Winter;8(1):1-11 [21404194.001]
  • [Cites] J Mol Diagn. 2012 Jul;14(4):385-92 [22580180.001]
  • [Cites] BMC Med. 2012 Sep 27;10:112 [23016578.001]
  • [Cites] Ther Adv Med Oncol. 2012 Jul;4(4):183-94 [22754592.001]
  • [Cites] Mol Oncol. 2013 Jun;7(3):732-8 [23587442.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2489-98 [12351585.001]
  • [Cites] Eur J Clin Invest. 2011 Nov;41(11):1245-53 [21521185.001]
  • [Cites] Trends Mol Med. 2010 May;16(5):230-7 [20434954.001]
  • [Cites] J Pathol. 2008 Dec;216(4):418-27 [18925646.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Cancer Biol Ther. 2010 Aug 1;10(3):219-22 [20592490.001]
  • [Cites] PLoS One. 2010 Dec 30;5(12):e15224 [21253009.001]
  • [Cites] BMC Med. 2010 Oct 21;8:65 [20964839.001]
  • [Cites] IUBMB Life. 2011 Feb;63(2):94-100 [21360638.001]
  • [Cites] Int J Urol. 2009 May;16(5):432-43 [19453547.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):375-83 [18624795.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2030-7 [19273703.001]
  • [Cites] J Urol. 2010 Nov;184(5):1877-81 [20850148.001]
  • [Cites] Eur Urol. 2011 May;59(5):721-30 [21272993.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1791-5 [8952515.001]
  • [Cites] Urology. 2010 Sep;76(3):610-3 [20163843.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • (PMID = 23587442.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


7. Schieda N, Al-Subhi M, Flood TA, El-Khodary M, McInnes MD: Diagnostic accuracy of segmental enhancement inversion for the diagnosis of renal oncocytoma using biphasic computed tomography (CT) and multiphase contrast-enhanced magnetic resonance imaging (MRI). Eur Radiol; 2014 Nov;24(11):2787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of segmental enhancement inversion for the diagnosis of renal oncocytoma using biphasic computed tomography (CT) and multiphase contrast-enhanced magnetic resonance imaging (MRI).
  • OBJECTIVES: Segmental enhancement inversion (SEI) is a controversial imaging finding reportedly specific for the diagnosis of renal oncocytoma.
  • METHODS: With research ethics board approval, a retrospective analysis of patients with resection or biopsy of oncocytoma or chromophobe renal cell carcinoma (Ch-RCC) between 2008-2012 was performed.
  • Twenty-four patients with oncocytoma and 13 patients with Ch-RCC underwent CT, while 13 patients with oncocytoma and 10 patients with Ch-RCC underwent MRI.
  • RESULTS: There was no difference in detection of SEI between oncocytoma and Ch-RCC at CT [both readers (p = 0.65, 0.5) and consensus review (p = 0.29)] or MRI [both readers (p = 0.64, 0.74) and consensus review (p = 0.53)].
  • The sensitivity and specificity for diagnosis of oncocytoma were 21 % and 92 % at CT and 15 % and 90 % at MRI.
  • CONCLUSION: SEI is not useful for the diagnosis of renal oncocytoma with CT or MRI.
  • • SEI is not useful for diagnosing renal oncocytoma with CT or MRI.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Contrast Media. Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Multidetector Computed Tomography / methods
  • [MeSH-minor] Aged. Biopsy, Large-Core Needle. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nephrectomy. ROC Curve. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Radiology. 2009 Aug;252(2):441-8 [19508984.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):355-9 [8493754.001]
  • [Cites] Fam Med. 2005 May;37(5):360-3 [15883903.001]
  • [Cites] J Urol. 2006 Sep;176(3):896-9 [16890647.001]
  • [Cites] AJR Am J Roentgenol. 2011 Oct;197(4):887-96 [21940576.001]
  • [Cites] Eur Radiol. 2014 Jun;24(6):1421-9 [24663821.001]
  • [Cites] Radiology. 1993 Mar;186(3):693-6 [8430176.001]
  • [Cites] Comput Radiol. 1985 Sep-Oct;9(5):307-14 [4064635.001]
  • [Cites] AJR Am J Roentgenol. 2011 Oct;197(4):W674-9 [21940539.001]
  • [Cites] AJR Am J Roentgenol. 2013 Sep;201(3):598-604 [23971452.001]
  • [Cites] AJR Am J Roentgenol. 2013 May;200(5):1054-9 [23617489.001]
  • [Cites] BJU Int. 2012 Dec;110(11 Pt B):E548-52 [22612453.001]
  • [Cites] Radiology. 1984 Oct;153(1):49-53 [6473802.001]
  • [Cites] AJR Am J Roentgenol. 2010 Dec;195(6):W421-7 [21098174.001]
  • [Cites] AJR Am J Roentgenol. 2012 Dec;199(6):1312-5 [23169723.001]
  • (PMID = 25027841.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; Oncocytoma, renal
  •  go-up   go-down


8. Ćirović S, Vještica J, Mueller CA, Tatić S, Vasiljević J, Milenković S, Mueller GA, Marković-Lipkovski J: NCAM and FGFR1 coexpression and colocalization in renal tumors. Int J Clin Exp Pathol; 2014;7(4):1402-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neural cell adhesion molecule (NCAM) and fibroblast growth factor receptor (FGFR) have a role in epithelial-mesenchymal transformation during tumor genesis.
  • Applying immunohistochemistry we revealed that the majority of analyzed renal neoplasms, including renal cell carcinoma (RCC) and oncocytoma coexpressed NCAM and FGFR1.
  • Interestingly, it seemed that different position of NCAM and FGFR1 expression on renal tumor cells is related to renal tumor type or grade: exclusively membranous FGFR1/NCAM expression occurred in low grade clear cell RCC (cRCC); cytoplasmatic and membranous expression was present in high grade cRCC and other RCC types; oncocytoma showed only cytoplasmatic staining of both markers.
  • Expression of both molecules on different cell compartments in various kidney tumors indicated that NCAM/FGFR1 interaction could play distinct roles in renal tumor genesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Neural Cell Adhesion Molecules / metabolism. Receptor, Fibroblast Growth Factor, Type 1 / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2000;196(2):135-9 [10707372.001]
  • [Cites] PLoS One. 2012;7(6):e38972 [22701738.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Structure. 2003 Jun;11(6):691-701 [12791257.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):528-32 [12827605.001]
  • [Cites] Structure. 2003 Oct;11(10):1291-301 [14527396.001]
  • [Cites] J Neurosci. 2004 Apr 28;24(17):4197-204 [15115815.001]
  • [Cites] Trends Genet. 2004 Nov;20(11):563-9 [15475116.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):275-86 [1867319.001]
  • [Cites] Neuron. 1994 Sep;13(3):583-94 [7917292.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 [15863030.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Mol Endocrinol. 2007 Apr;21(4):987-1000 [17284663.001]
  • [Cites] Nephrol Dial Transplant. 2007 Jun;22(6):1558-66 [17337466.001]
  • [Cites] Protein Sci. 2008 Oct;17(10):1698-705 [18593816.001]
  • [Cites] EMBO J. 2008 Oct 8;27(19):2603-15 [18772882.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1160-71 [19246644.001]
  • [Cites] PLoS One. 2009;4(8):e6709 [19696931.001]
  • [Cites] J Cell Biol. 2009 Dec 28;187(7):1101-16 [20038681.001]
  • [Cites] Diagn Pathol. 2010;5:28 [20462442.001]
  • [Cites] Scand J Urol Nephrol. 2011 Apr;45(3):190-5 [21329481.001]
  • [Cites] EMBO Mol Med. 2011 Aug;3(8):480-94 [21739604.001]
  • [Cites] J Cell Sci. 2011 Sep 15;124(Pt 18):3106-17 [21868365.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):650-7 [11433297.001]
  • (PMID = 24817936.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; Oncocytoma, renal
  • [Other-IDs] NLM/ PMC4014220
  • [Keywords] NOTNLM ; FGFR1 / NCAM / coexpression / colocalization / renal tumors
  •  go-up   go-down


9. Heindl LM, Treutlein E, Jünemann AG, Kruse FE, Holbach LM: [Selective lacrimal sac biopsy for external dacryocystorhinostomy: a clinical pathological study]. Ophthalmologe; 2010 Dec;107(12):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lacrimal sac biopsy was performed in 19 external dacryocystorhinostomies (3.8%) including non-Hodgkin B-cell lymphoma (3), squamous carcinoma (2), mucoepidermoid carcinoma (1), malignant melanoma (1), oncocytoma (1), pyogenic granuloma (4), Wegener's granulomatosis (4) and sarcoidosis (3).

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2002 Jul;109 (7):1214-7; discussion 1217-8 [12093640.001]
  • [Cites] Ophthalmologe. 2008 Dec;105(12):1146-9 [18438631.001]
  • [Cites] Ophthalmology. 1986 Aug;93(8):1055-63 [3763155.001]
  • [Cites] Ophthalmologe. 1994 Jun;91(3):395-8 [8086760.001]
  • [Cites] Ophthalmology. 1997 Nov;104(11):1882-6 [9373121.001]
  • [Cites] Eye (Lond). 2003 Jul;17(5):599-606 [12855966.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1992;8(4):237-42 [1476972.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Mar-Apr;22(2):96-101 [16550051.001]
  • [Cites] Ophthalmologe. 2004 Jul;101(7):730-2 [15309490.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):173-6 [12918549.001]
  • [Cites] Am J Ophthalmol. 2005 Jun;139(6):1051-5 [15953435.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1992;8(1):13-21 [1554647.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2038-40 [11713075.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Sep;10 (3):169-84 [7947444.001]
  • [Cites] Br J Ophthalmol. 2005 Dec;89(12):1589-91 [16299137.001]
  • [Cites] Orbit. 2009;28(1):7-11 [19229737.001]
  • (PMID = 20535481.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Choi JH, Kim JW, Lee JY, Han WK, Rha KH, Choi YD, Hong SJ, Yoon YE: Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas. Korean J Urol; 2015 Oct;56(10):695-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas.
  • PURPOSE: To investigate and distinguish the computed tomography (CT) characteristics of chromophobe renal cell carcinoma (chRCC) and renal oncocytoma.
  • MATERIALS AND METHODS: Fifty-one patients with renal oncocytoma and 120 patients with chRCC, diagnosed by surgery between November 2005 and June 2015, were studied retrospectively.
  • Receiver-operating characteristic curve analysis showed that the presence of a central stellate scar and higher mean HU values in the nephrogenic phase were highly predictive of renal oncocytoma (area under the curve=0.817, p<0.001).
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Carcinoma, Renal Cell / radiography. Kidney Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2011 Aug;60(2):241-8 [21458155.001]
  • [Cites] Radiology. 2010 May;255(2):501-7 [20160001.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:134 [19811659.001]
  • [Cites] Radiology. 2009 Aug;252(2):441-8 [19508984.001]
  • [Cites] J Urol. 2009 Sep;182(3):844-53 [19616235.001]
  • [Cites] Radiology. 2008 May;247(2):331-43 [18310461.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Am J Clin Pathol. 1998 Dec;110(6):782-7 [9844591.001]
  • [Cites] Hinyokika Kiyo. 1994 Jan;40(1):47-50 [8109473.001]
  • [Cites] Am J Hypertens. 2000 Apr;13(4 Pt 1):346-52 [10821334.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):935-42 [12792905.001]
  • [Cites] J Urol. 2012 Dec;188(6):2072-6 [23083863.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1983;398(3):291-304 [6402840.001]
  • [Cites] Acta Radiol. 2016 Apr;57(4):500-6 [25972369.001]
  • [Cites] Eur Radiol. 2014 Jun;24(6):1421-9 [24663821.001]
  • [Cites] J Clin Pathol. 2014 Feb;67(2):97-104 [24170213.001]
  • [Cites] AJR Am J Roentgenol. 2013 Sep;201(3):598-604 [23971452.001]
  • [Cites] Urology. 2013 Jun;81(6):1265-71 [23601445.001]
  • (PMID = 26495070.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] Oncocytoma, renal
  • [Other-IDs] NLM/ PMC4610896
  • [Keywords] NOTNLM ; Renal cell carcinoma / Renal oncocytoma / X-ray computed tomography
  •  go-up   go-down






Advertisement